Skip to main content

Catalyst Calendar

Scope
Catalyst

Mon, Sep 14, 2026

1 updates
AZN
2:00 AM

Update on SERENA-4 Phase III trial

This announcement contains inside information 14 September 2026 Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer SERENA-4 trial did not meet primary objective of statistically significant improvement in progression-free survival, however a numerical improvement was observed...

Trial Results • Phase 3SERENA-4 trial results Mon, Sep 14, 2026, 8:00 AM CETastrazeneca.com

Tue, Sep 8, 2026

1 updates
AZN
9:00 AM

Imfinzi+Imdelltra improved OS in small cell lung

8 September 2026 Imfinzi plus Imdelltra demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer Imfinzi is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting...

Trial Results • Phase 3Results event Tue, Sep 8, 2026astrazeneca.com

Tue, Sep 1, 2026

1 updates
AZN
2:00 AM

Tagrisso + Orpathys improved PFS in 1L EGFRm lung

1 September 2026 Tagrisso plusOrpathysdemonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer Results of SANOVO Phase III trial in China build on established success of global SAFFRON and China SACHI trials, extending clinical value of the...

Trial Results • Phase 3oral presentation Tue, Sep 1, 2026astrazeneca.com

Thu, Aug 27, 2026

1 updates
AZN
2:15 AM

Tezspire CROSSING trial met primary endpoints

27 August 2026 Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52 Efficacy in a third epithelial-driven inflammatory disease supports broad...

Trial Results • Phase 3Results event Thu, Aug 27, 2026astrazeneca.com